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Abstract
Background
Self-report is the most common and feasible method for assessing patient adherence to
medication, but can be prone to recall bias and social desirability bias. Most studies assess-
ing adherence to artemisinin-based combination therapies (ACTs) have relied on self-
report. In this study, we use a novel customised electronic monitoring device—termed
smart blister packs—to examine the validity of self-reported adherence to artemether-lume-
fantrine (AL) in southern Tanzania.
Methods
Smart blister packs were designed to look identical to locally available AL blister packs and
to record the date and time each tablet was removed from packaging. Patients obtaining AL
at randomly selected health facilities and drug stores were followed up at home three days
later and interviewed about each dose of AL taken. Blister packs were requested for pill
count and extraction of smart blister pack data.
Results
Data on adherence from both self-report verified by pill count and smart blister packs were
available for 696 of 1,204 patients. There was no difference between methods in the propor-
tion of patients assessed to have completed treatment (64% and 67%, respectively). How-
ever, the percentage taking the correct number of pills for each dose at the correct times
(timely completion) was higher by self-report than smart blister packs (37% vs. 24%;
PLOSONE | DOI:10.1371/journal.pone.0134275 July 27, 2015 1 / 18
OPEN ACCESS
Citation: Bruxvoort K, Festo C, Cairns M, Kalolella A,
Mayaya F, Kachur SP, et al. (2015) Measuring Patient
Adherence to Malaria Treatment: A Comparison of
Results from Self-Report and a Customised
Electronic Monitoring Device. PLoS ONE 10(7):
e0134275. doi:10.1371/journal.pone.0134275
Editor: Henk D. F. H. Schallig, Royal Tropical
Institute, NETHERLANDS
Received: February 19, 2015
Accepted: July 7, 2015
Published: July 27, 2015
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced, distributed,
transmitted, modified, built upon, or otherwise used
by anyone for any lawful purpose. The work is made
available under the Creative Commons CC0 public
domain dedication.
Data Availability Statement: Data are available from
the London School of Hygiene and Tropical Medicine
Data Compass and can be accessed at http://dx.doi.
org/10.17037/DATA.3.
Funding: The study was funded by the Bill and
Melinda Gates Foundation, through a grant to the
ACT Consortium. MC is supported by a fellowship
jointly funded by the UK Medical Research Council
(MRC) and the UK Department for International
Development (DFID) under the MRC/DFID Concordat
agreement. KB, MC, DS, and CG are members of the
LSHTM Malaria Centre.
p<0.0001). By smart blister packs, 64% of patients completing treatment did not take the
correct number of pills per dose or did not take each dose at the correct time interval.
Conclusion
Smart blister packs resulted in lower estimates of timely completion of AL and may be less
prone to recall and social desirability bias. They may be useful when data on patterns of
adherence are desirable to evaluate treatment outcomes. Improved methods of collecting
self-reported data are needed to minimise bias and maximise comparability between
studies.
Introduction
Self-reported adherence, based on detailed questionnaires, is considered the most feasible
method for assessing adherence in resource-poor settings [1, 2]. Self-reported data are rela-
tively low cost to collect and do not involve complicated field logistics or invasive procedures
such as blood sampling. However, despite its many advantages, self-reported adherence is
prone to several sources of bias [2–4]. Data may be subject to recall bias if patients do not accu-
rately recall their treatment history, including the number of pills taken, day and time of each
dose, and when the full course was completed. Social desirability bias may also occur if patients
provide perceived expected responses in order to avoid being seen as negligent.
Several other methods have been used to complement or even replace patient recall. Many
studies verify self-reported adherence by counting the number of pills remaining in packaging,
although this is not always accurate as patients may remove pills without taking them, or pack-
aging may not be available for inspection [5, 6]. Electronic methods of assessing adherence
have been used extensively in chronic diseases, mostly in the form of pill containers with caps
that record the day and time the container is opened, such as Medication Events Monitoring
Systems (MEMS) [4, 7]. While not feasible for routine clinical practice in many parts of the
world, MEMS have been used to validate other adherence measures in studies of adherence to
antimalarial drugs [8, 9], tuberculosis treatment [10], and antiretroviral therapy [11].
Artemisinin-based combination therapies (ACTs) are first line treatment for malaria in
most endemic countries and are increasingly obtained by patients seeking treatment in both
public and private health sectors. Good patient adherence is required to maximise their clinical
impact and minimise the rate of development of drug-resistance [12–14]. A number of studies
assessing adherence to ACTs have been conducted in recent years, with results showing that
anywhere between 39% and 100% of patients can be considered adherent [5, 6], reflecting both
genuine differences in adherence as well as variation in study design and measurement meth-
ods. The majority of these studies relied on self-report with or without pill count. One study in
Malawi used MEMS containers and found 100% adherence to artemether-lumefantrine (AL)
by self-report and lower adherence (92%) by MEMS [8]. However, ACTs are now typically dis-
pensed in blister packs designed to improve adherence [15] and look considerably different
than MEMS containers. This may result in over-estimated adherence, as patients using MEMS
are likely to be aware that their adherence is being monitored and their experience is no longer
comparable to that of patients receiving unit doses in their customary packaging.
In this study, set in southern Tanzania, the validity of self-reported patient adherence to AL
was assessed using a novel customised electronic monitoring device—termed smart blister
packs—that looked identical to regular AL packs, but contained a device that registered the
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date and time each pill was removed from the pack. This is the first study to our knowledge to
employ this technology under routine conditions to investigate adherence to antimalarial
treatment.
Methods
Study setting
The study was conducted in Mtwara, a rural region in southeastern Tanzania with more than a
third of the population in the lowest national wealth quintile [16]. Community prevalence of
falciparum malaria parasitaemia among children 6–59 months of age in Mtwara was 17.4% in
the 2011–2012 HIV/AIDS and Malaria Indicator Survey [17].
In Tanzania, AL was introduced in public health facilities for treatment of uncomplicated
malaria in 2006. The recommended treatment regimen is six doses over 3 days, with 1–4 tablets
(each containing 20 mg artemether / 120 mg lumefantrine) per dose depending on the patient's
weight / age band. National guidelines state that the second dose should be taken eight hours
after the first dose, followed by the remaining doses each morning and evening of the second
and third days [18].
In Tanzania’s private sector, more than two thirds of antimalarial drug sales occur in small
drug stores [19], many of which have been upgraded to Accredited Drug Dispensing Outlets
(ADDOs) through a process of training and accreditation. ADDOs are allowed to sell a limited
number of prescription-only drugs, including some antibiotics and ACTs [20, 21]. By 2011, all
drug shops in Mtwara were officially required to have upgraded to ADDO status, but in prac-
tice some shops had not yet paid fees or received training and were tolerated as “prospective
ADDOs” (in this paper the term ADDOs is used to include both accredited outlets and “pro-
spective ADDOs”).
This study was embedded in two parallel and contemporaneous studies of adherence to AL:
a cluster randomised trial of a text message intervention targeted at ADDO dispensers to
improve knowledge of advice to provide when dispensing AL, and an observational adherence
study in public health facilities. Details and results of these studies are presented separately [22,
23]. Smart blister pack data were collected from a subset of patients in both studies for the anal-
yses reported here.
Smart blister packs
Smart blister packs were prepared using Med-ic blister package technology (Information Medi-
ary Corporation, Ottawa, Canada). This comprises a fine wire, connected to a microchip,
across each blister. When a tablet is pushed through the foil, the wire is disrupted, and the pre-
cise date and time this occurs is recorded on the chip. Wallet cards were designed for all four
weight / age bands of AL (Coartem) and looked identical to AL locally available in Tanzania,
but with a slight thickness near the top centre illustrations due to the electronic tag and cell bat-
tery (Fig 1). Smart blister packs were assembled by research assistants at the Ifakara Health
Institute by folding the wallet cards around blister packs of Coartem purchased in Tanzania
and sealing adhesively. The blister packs were activated prior to the study by scanning with a
portable device developed by Information Mediary Corporation, allowing dates and times to
be recorded. Following treatment, collected blister packs were scanned to retrieve data, and
intervals between timestamps were calculated.
Comparison of Methods to Assess Adherence to Malaria Treatment
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Fig 1. Picture of a smart blister pack showing resemblance to regular blister packs.
doi:10.1371/journal.pone.0134275.g001
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Sample size and selection of study outlets
We aimed to provide smart blister packs to all 936 patients required for the cluster randomised
trial in ADDOs [22] and all 448 patients required for the observational adherence study in
public health facilities [23]. However, we also explored with what precision we could estimate
sensitivity and specificity of self-report compared to smart blister packs. The calculations indi-
cated that, assuming conservatively that sensitivity and specificity of self-report were 50%, with
a true adherence of 60% and a design effect due to correlation of responses within outlets of
2.5, 600 patients with both self-report and smart blister pack data were sufficient to estimate
sensitivity and specificity with a precision of 10 percentage points [24]. A small number of
patients per outlet was desired in order to reduce any potential bias caused by increasing com-
munity awareness of the study's objectives. Thus, 40 public health facilities (but not hospitals)
were randomly selected from a list of all dispensaries and health centres in Mtwara, and 82
ADDOs meeting study inclusion criteria [22] were randomly selected from a census register of
all ADDOs in Mtwara.
Study procedures
From September through November 2012, dispensers at selected public health facilities and
ADDOs were visited by study supervisors and given a standard introduction about the study's
objectives. Dispensers were provided with smart blister packs of AL to be dispensed in public
health facilities to patients prescribed ACTs, and in ADDOs to patients indicating an intention
to purchase treatment for malaria. In order to limit patients’ awareness of our primary interest
in assessing adherence, which could have led to a biased assessment, dispensers were not told
that the blister packs provided were any different than the regular AL packs used locally. Dis-
pensers were told we would visit at home some, but not all, patients obtaining treatment for
fever and were asked to fill out a registration form for all fever patients, including a description
of where patients lived. Study staff visited outlets every day to check and collect registration
forms. The intention was to register 12 patients obtaining ACTs in one week per outlet, but it
took 2–3 weeks to recruit this number in some outlets.
Eligible patients who obtained AL were identified from the registration forms and followed
up three days later (day 4). Where written informed consent was given, patients / caregivers
were asked about demographic and socioeconomic characteristics, treatment-seeking history,
symptoms, detailed information about each dose of AL taken, and advice provided by the dis-
penser. The blister packs were requested for a pill count and extraction of timestamp data, fol-
lowing a brief explanation of the nature and purpose of the smart blister packs. Blood samples
were collected for a blood smear, a histidine-rich protein II (HRP-2)-based malaria rapid diag-
nostic test (mRDT) (Pf-specific from ICT Diagnostics, Cape Town, South Africa), and a filter
paper dried blood spot (Whatman FTA DMPK B card, GE Healthcare). Results of blood
smears and mRDTs are discussed in a previous paper [23]. Filter papers were transferred to the
University Hospital in Lausanne, Switzerland, where they were analysed for blood concentra-
tion of lumefantrine by high performance liquid chromatography coupled to tandem mass
spectrometry (LC-MS/MS). Due to technical problems that arose, these results are not shown,
but the issue is addressed in the Discussion.
Adherence definitions
Adherence was defined by both self-report and smart blister packs in two ways: verified com-
pleted treatment and verified timely completion [5]. Patients were considered to have verified
completed treatment (hereafter termed completed treatment) by self-report if they reported
taking all pills by the time of the follow up visit, verified by counting zero pills remaining in
Comparison of Methods to Assess Adherence to Malaria Treatment
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packaging. Patients who reported completing treatment but had pills remaining were consid-
ered non-adherent, as were patients who reported not completing treatment but presented an
empty blister pack. Where blister packs were not available, self-report alone determined if
patients completed treatment. By smart blister pack, patients were considered to have com-
pleted treatment if a timestamp was recorded for each pill by the time of the follow up visit.
Verified timely completion (hereafter termed timely completion) was a more stringent defi-
nition and included a time component. For self-report, Swahili times of day were used: “alfajiri”
(early morning, defined here as 4:00 am–6:59 am), “asubuhi” (morning, 7:00 am–11:59 am),
“mchana” (afternoon, 12:00 pm–3:59 pm), “jioni” (evening, 4:00 pm–6:59 pm), “usiku” (night,
7:00 pm–9:59 pm), and “usiku sana” (late night, 10:00 pm–3:59 am). Patients were considered
to have self-reported timely completion if they took the correct number of pills for each dose
and took each dose at the correct Swahili time of day. The second dose was considered correct
if taken at the Swahili times of day corresponding with 8 hours after the beginning or end of
the time interval for the Swahili time of day when the first dose was taken. For example, if the
first dose was taken in the morning (“asubuhi”), then the second dose could be taken in the
afternoon (“mchana”), evening (“jioni”), or night (“usiku”) of the same day (i.e. between 3:00
pm and 7:59 pm). Remaining doses were considered correct if taken at the Swahili times of day
corresponding with 12 hours after the beginning or end of the time interval for the Swahili
time of day when the previous dose was taken. As with completed treatment, examination of
packaging when available was used to verify adherence.
By smart blister pack, patients were considered to have timely completion if they took the
correct number of pills for each dose, and took the second dose eight hours plus or minus four
hours after the first dose, followed by taking each of the remaining doses 12 hours plus or
minus four hours after the previous dose.
For describing non-adherence, we distinguish between “intended doses” and “actual doses.”
“Intended dose” refers to the pills that are intended by the manufacturer to be taken together at
one of six specified times and, in the AL used in this study, grouped together in the blister pack-
aging. “Actual dose” refers to pills that were actually taken together. An actual dose might have
included pills that were not grouped together, or a different number than specified for the
intended dose. Pills that were administered at least 30 minutes apart from each other were con-
sidered different actual doses.
Data entry and analysis
All patient and dispenser interview data were collected using personal digital assistants, and
data extracted from study forms (census, registration, and follow-up forms) were double
entered into a Microsoft Access databases. Data were analysed in Stata 11.0 (Stata Corporation,
College Station, USA). Confidence intervals for percentages were calculated using a linearized
variance estimator, a robust standard error that accounts for the study design. McNemar’s
analysis for paired data and conditional logistic regression were used to test the difference in
completed treatment and timely completion between self-report and smart blister packs.
Ethics
All questionnaires, consent forms, and other study documents were translated into Swahili and
piloted prior to use. Written informed consent was collected from dispensers prior to census,
patient registration, and interview and from patients or their caregivers prior to interview. The
study protocol was approved by the ethical review boards of Ifakara Health Institute and Lon-
don School of Hygiene and Tropical Medicine. CDC advisors provided technical assistance in
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design and analysis but were not engaged in data collection and did not have access to personal
identifiers.
Results
Interviews were conducted with 1,204 patients from 117 outlets (five ADDOs were closed or
refused to participate). Blister packs were not available for collection from 256 patients (21%).
Smart blister packs that had been damaged or from which data were not extractable were col-
lected from 252 patients (21%). In total, data were extracted from the blister packs of 696
patients (58%) (Fig 2). Due to infeasible dosing patterns or errors in smart blister pack technol-
ogy, 55 patients were excluded from the analysis of timely completion, but not the analysis of
completed treatment, since pills remained in their blister packs. For self-report, this applied to
18 patients who reported taking a subsequent dose before an earlier dose. For smart blister
pack data, this applied to 10 patients with timestamps recorded before the treatment was dis-
pensed or after the pack was collected, and 27 patients with a different number of pills observed
by the study team at scanning than the number read by the software.
Table 1 shows characteristics of patients with both smart blister pack data and self-reported
data available and patients with only self-reported data available (results comparing patient
characteristics and adherence to AL across outlet types are presented elsewhere [21]). Based on
the recommended age groups for AL blister packs in Tanzania, 27% of the 696 patients with
both smart blister pack and self-reported data available were in the youngest age group (under
Fig 2. Flow chart of patients included in analysis.
doi:10.1371/journal.pone.0134275.g002
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three years), 24% were three years to under eight years, 6% were eight years to under 12 years,
and 43% were 12 years and above. Fewer patients with only self-reported data available were
under three years (21%) and more were 12 years and older (50%). Taking the first dose at the
outlet was reported by 23% of patients with both smart blister pack and self-reported data
available and 17% with only self-reported data available (p = 0.0281), but all other characteris-
tics were similar for patients with and without both types of data. Given that some differences
were observed, comparisons between methods were restricted to patients with both self-report
and smart blister pack data available.
Comparison of adherence by self-report and smart blister pack data
Completed treatment. For patients with both types of data available, estimates of com-
pleted treatment were similar by smart blister packs (67%) and self-report (64%), with little dif-
ference in adherence by weight / age band of AL (Table 2). Considering smart blister packs as a
gold standard, sensitivity and specificity of self-reported adherence were 96% and 100% respec-
tively (S1 Table). It was not possible to calculate an odds ratio because there were no instances
where patients who reported completing treatment did not complete treatment by smart blister
pack data.
Among patients who did not present blister packs for collection, self-reported completed
treatment was higher (87%) compared to both all patients who presented blister packs (66%;
p<0.0001) and patients for whom smart blister pack data were available (64%; p<0.0001).
Self-reported completed treatment was slightly lower among patients with smart blister pack
Table 1. Characteristics of patients with and without self-report and smart blister pack data available (percent (number))1,2.
Patients with both smart blister pack and self-
reported data available (N = 696)1
Patients with only self-reported
data available (N = 508)2
p-
value
Male 45.3 (315) 48.0 (244) 0.3
Age3 0.0249
Under 3 years 26.9 (187) 21.1 (107)
3 years to under 8 years 23.8 (166) 21.3 (108)
8 years to under 12 years 5.8 (40) 8.1 (41)
12 years and above 43.5 (303) 49.6 (252)
Patient (or caregiver if patient below age 12
years) completed primary school
70.9 (490) 71.0 (360) 0.9
Slept under net the night before the interview 72.2 (502) 76.7 (388) 0.1
Attended an outlet in an urban ward 47.6 (331) 50.8 (258) 0.4
Attended ADDO (vs. public health facility) 64.2 (447) 66.9 (340) 0.2
Distance of 2.5 km or less from home to outlet
(by GPS coordinates)
73.9 (468) 75.2 (340) 0.6
Reported being tested for malaria at outlet 26.4 (183) 24.2 (122) 0.5
Reported taking ﬁrst dose of AL at the outlet 22.8 (158) 17.4 (88) 0.0281
Reported receiving correct instructions on AL
regimen4
59.6 (281) 57.3 (291) 0.4
1 For patients with smart blister pack data and self-reported data available, data were missing for education for 5 patients, net use for 1 patient, GPS data
for 63 patients, being tested for malaria for 2 patients, and taking the ﬁrst dose of AL at the outlet for 4 patients.
2 For patients with only self-reported data available, data were missing for education for 3 patients, net use for 2 patients, GPS data for 73 patients, being
tested for malaria for 5 patients, and taking the ﬁrst dose of AL at the outlet for 2 patients.
3Age categories based on recommended age breakdown for AL blister packs in Tanzania.
4Reported the correct number of pills per dose, the correct number of doses per day, and the correct number of days per dispenser instructions.
doi:10.1371/journal.pone.0134275.t001
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data available (64%) than among patients presenting damaged smart blister packs from which
data were not extractable (72%; p = 0.050).
Timely completion. Timely completion was 37% by self-report and 24% by smart blister
pack data (Table 3), much lower than completed treatment. The odds of timely completion by
smart blister pack data were 0.36 times that of self-report (95% CI: 0.29, 0.43, p<0.0001). Sen-
sitivity and specificity of self-reported timely completion were 74% and 74% respectively (S2
Table). Although the number of patients ages eight to 12 years with a 3x6 pack was relatively
small, this group appeared to have slightly higher timely completion, especially by smart blister
pack data (Table 3), than patients taking other packs. Adult patients (with 4x6 packs) also
appeared to have slightly higher timely completion than the two youngest age groups according
to smart blister pack data, but not self-report.
Timely completion consisted of two aspects, taking the correct number of pills for each dose
and taking all six doses at the correct time intervals. Of the 418 patients with data on timely
completion available who reported having completed treatment (Table 3), 97% reported taking
the correct number of pills for each of six actual doses. In contrast, according to smart blister
pack data, only 67% of the 436 patients completing treatment appeared to have taken the cor-
rect number of pills for each of six actual doses, a finding more pronounced for younger chil-
dren than older children and adults. Of patients who reported completing treatment, 58%
reported taking all six doses at the correct time intervals, compared with 40% of those complet-
ing treatment based on smart blister pack data. Thus, by self-report, correct time intervals were
the primary obstacle for timely completion among patients who had completed treatment, but
the smart blister pack data revealed problems both with the correct number of pills for each
dose and the correct time intervals between doses.
Patterns of non-adherence
Fig 3 shows the number of actual doses taken, ranging from 0–6 by self-report and from 0–8 by
smart blister pack data. Overall, the proportions reporting completion of each dose were simi-
lar, except that by self-report more people reported taking six doses. This may be because
Table 2. Completed treatment by self-report and smart blister packs.
Self-report Smart blister packs
Number with self-reported data and electronic blister pack
data available (N)
696 696
Percent completed treatment (numerator / denominator)
(95% CI)
Total1 64.1 (446/696) (59.8,
68.1)
66.7 (464/696) (62.3,
70.7)
1x6 (6 tablets) 65.1 (162/249) (58.2,
71.4)
65.5 (163/249) (58.8,
71.6)
2x6 (12 tablets) 64.5 (80/124) (55.9,
72.3)
66.9 (83/124) (58.2,
74.6)
3x6 (18 tablets) 53.7 (22/41) (39.8,
67.0)
61.0 (25/41) (46.0,
74.1)
4x6 (24 tablets) 64.5 (182/282) (58.6,
70.1)
68.4 (193/282) (62.2,
74.1)
1An odds ratio for the effect of measurement method on completed treatment could not be calculated
because there were zero patients who reported completing treatment but did not complete treatment by
smart blister pack data.
doi:10.1371/journal.pone.0134275.t002
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patients were asked only about each of the six intended doses. Only about 5% of patients took
more than six actual doses according to smart blister pack data, including both patients who
completed treatment and those who did not (Fig 3 and Table 4). For both self-report and smart
blister pack data, the median numbers of actual doses taken by patients who did not complete
treatment were 4 for the 1x6 and 2x6 packs and 5 for the 3x6 and 4x6 packs. By self-report and
smart blister pack data, respectively, the median total numbers of pills taken for patients who
did not complete treatment were 4 and 4.5 for the 1x6 pack, 8 (by both methods) for the 2x6
pack, 15 and 13.5 for the 3x6 pack, and 20 (by both methods) for the 4x6 pack (Table 4).
For the first actual dose, timely completion (based only on taking the correct number of
pills for each dose, as timeliness of the first dose was not assessed) was 98% by self-report and
87% by smart blister pack data. Timely completion for the second actual dose decreased to 71%
by both self-report and smart blister pack data (Fig 4). For the third dose onward, timely
Table 3. Timely completion by self-report and smart blister packs1 (percent (number)).
Self-report1 Smart blister packs1
Patients completing treatment All patients Patients completing treatment All patients
Total 418 641 436 641
1x6 (6 tablets) 154 239 155 239
2x6 (12 tablets) 77 121 80 121
3x6 (18 tablets) 21 36 24 36
4x6 (24 tablets) 166 245 177 245
Percent taking the correct number of pills for each of six actual doses2,3
Total 96.9 (405) 63.5 (407) 67.2 (293) 45.7 (293)
1x6 (6 tablets) 96.1 (148) 62.3 (149) 75.5 (117) 49.0 (117)
2x6 (12 tablets) 98.7 (76) 62.8 (76) 71.3 (57) 47.1 (57)
3x6 (18 tablets) 100 (21) 58.3 (21) 62.5 (15) 41.7 (15)
4x6 (24 tablets) 96.4 (160) 65.7 (161) 58.8 (104) 42.5 (104)
Percent taking six actual doses at the correct time intervals: 4,5
Total 58.4 (244) 39.6 (254) 40.4 (176) 27.6 (177)
1x6 (6 tablets) 57.8 (89) 38.1 (91) 32.9 (51) 21.3 (51)
2x6 (12 tablets) 58.4 (45) 38.0 (46) 36.3 (29) 24.8 (30)
3x6 (18 tablets) 71.4 (15) 44.4 (16) 54.2 (13) 36.1 (13)
4x6 (24 tablets) 57.2 (95) 41.2 (101) 46.9 (83) 33.9 (83)
Timely completion (Percent taking the correct number of pills at the correct time intervals for each of six actual doses):
Total6 57.4 (240) 37.4 (240) 35.6 (155) 24.2 (155)
1x6 (6 tablets) 56.5 (87) 36.4 (87) 32.9 (51) 21.3 (51)
2x6 (12 tablets) 58.4 (45) 37.2 (45) 32.5 (26) 21.5 (26)
3x6 (18 tablets) 71.4 (15) 41.7 (15) 50.0 (12) 33.3 (12)
4x6 (24 tablets) 56.0 (93) 38.0 (93) 37.3 (66) 26.9 (66)
155 patients were excluded from this analysis because data on timing of each actual dose were not possible to assess for self-report for 18 patients and
for smart blister pack data for 37 patients.
2
“Actual doses” refers to pills actually taken together, including pills that were not grouped together, or a different number than speciﬁed for the intended
dose. Pills administered at least 30 minutes apart from each other were considered different actual doses.
3 By self-report, number of pills taken missing for one dose for 2 patients for the 1x6 pack, 1 patient for the 2x6 pack, and 8 patients for the 4x6 pack.
4 By self-report, time of taking one or more doses missing for 24 patients for the 1x6 pack, 12 patients for the 2x6 pack, 2 patients for the 3x6 pack, and 20
patients for the 4x6 pack.
5By smart blister pack data, no patients who completed treatment and took more than six actual doses took the ﬁrst six at the correct intervals.
6 For all patients (total columns) the odds ratio for timely completion by smart blister pack vs. self-report was 0.36, 95% CI: 0.29, 0.42; p<0.0001.
doi:10.1371/journal.pone.0134275.t003
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completion by self-report was clearly higher than for the second dose (above 80%), but this
increase was not evident in the smart blister pack data. Cumulatively, timely completion after
two actual doses was similar for self-report and smart blister pack data, reflecting a slightly
larger drop in timely completion by self-report. From dose three onwards, timely completion
declined more rapidly by smart blister pack data.
Discussion
This paper examines the validity of self-reported adherence in comparison with smart blister
packs that recorded the day and time pills were removed from packaging. Timely completion
(37% by self-report and 24% by smart blister packs) was much lower than completed treatment
(64% by self-report and 67% by smart blister packs). No difference was observed between self-
report and smart blister pack data for the percentage of patients completing treatment, but
timely completion was lower when assessed using smart blister pack data (OR = 0.36, 95% CI:
0.29, 0.42, p<0.0001). Smart blister pack data showed that, even among patients who com-
pleted treatment, 33% did not take the correct number of pills for all doses, and 60% did not
take each dose at the correct time interval.
This study has several limitations. First, recovery of blister packs might have been higher
had dispensers and patients been more aware of the aims of the study. However, to avoid artifi-
cially increasing adherence, we intentionally did not tell dispensers or patients that the objec-
tive of the study was to assess adherence. Secondly, dispensers did not always accurately record
the time that drugs were dispensed, despite daily visits by the study team and attempts to clarify
times that were unclear. We therefore concluded that the data were not sufficiently robust to
assess the timeliness of the first dose.
For both self-report and smart blister pack data, we allowed a margin of error around the
correct time intervals when assessing timely completion. Clocks are not commonly used in
Fig 3. Number of actual doses taken by self-report and smart blister packs1–3. 155 patients were excluded from this analysis because data on timing of
each actual dose were not possible to assess for self-report for 18 patients and for smart blister pack data for 37 patients. 2“Actual doses” refers to pills
actually taken together, including pills that were not grouped together, or a different number than specified for the intended dose. Pills administered at least
30 minutes apart from each other were considered different actual doses. 3By self-report, patients were asked only about each of the six intended doses.
doi:10.1371/journal.pone.0134275.g003
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rural Mtwara, and Swahili times of day which each cover several hours were therefore used for
self-reported timely completion. Recorded timestamps plus or minus four hours were used to
define acceptable limits for smart blister pack data. Among patients with timely completion by
both methods, Swahili times of day corresponded well with timestamps, so it is unlikely that
the definitions of timely completion affected the difference between methods. However, more
stringent definitions for both methods might have resulted in lower levels of timely completion.
Variability in adherence definitions has been frequently noted as a challenge for comparing
adherence results across studies [5, 6, 25].
Self-report and smart blister pack data have various advantages and disadvantages for
assessing patient adherence to ACTs. Self-reported adherence is collected through interviews,
which are relatively inexpensive and are a widely accepted method of collecting data in many
populations, including in southern Tanzania. Nonetheless, collecting accurate self-reported
data can be challenging. Patients may have provided expected answers on the number of pills
taken for each dose, or not remembered, and interviewers reported that patients often seemed
confused about when and how each dose was taken. Some patients reporting taking more pills
in total than the number in the blister pack, and some reported taking a subsequent dose before
a previous dose. In this study, specific questions were asked about each of the six intended
Table 4. Median number of actual doses and pills taken by self-report and smart blister packs 1.
Self-report1 Smart blister packs1
Patients completing
treatment
Patients not completing
treatment
All
patients
Patients completing
treatment
Patients not completing
treatment
All
patients
Total 418 223 641 436 205 641
1x6 (6 tablets) 154 85 239 155 84 239
2x6 (12 tablets) 77 44 121 80 41 121
3x6 (18 tablets) 21 15 36 24 12 36
4x6 (24 tablets) 166 79 245 177 68 245
Median (range) number of actual doses taken2
Total 6 (6–6) 5 (0–6) 6 (0–6) 6 (1–8) 4 (0–7) 6 (0–8)
1x6 (6 tablets) 6 (6–6) 4 (1–5) 6 (1–6) 6 (1–6) 4 (1–5) 5 (1–6)
2x6 (12 tablets) 6 (6–6) 4 (0–5) 6 (0–6) 6 (1–7) 4 (1–7) 6 (1–7)
3x6 (18 tablets) 6 (6–6) 5 (2–6) 6 (2–6) 6 (1–8) 5 (2–6) 6 (1–8)
4x6 (24 tablets) 6 (6–6) 5 (0–6) 6 (0–6) 6 (1–8) 5 (0–7) 6 (0–8)
Median (range) number of pills taken3,4
1x6 (6 tablets) 6 (6–7) 4 (1–6) 6 (1–7) 6 (6–6) 4.5 (1–5) 6 (1–6)
2x6 (12 tablets) 12 (12–13) 8 (0–12) 12 (0–13) 12 (12–12) 8 (1–11) 12 (1–12)
3x6 (18 tablets) 18 (18–18) 15 (6–15) 18 (6–18) 18 (18–18) 13.5 (6–15) 18 (6–18)
4x6 (24 tablets) 24 (24–24) 20 (0–24) 24 (0–24 24 (24–24) 20 (0–22) 24 (0–24)
155 patients were excluded from this analysis because data on timing of each actual dose were not possible to assess for self-report for 18 patients and
for smart blister pack data for 37 patients.
2
“Actual doses” refers to pills actually taken together, including pills that were not grouped together, or a different number than speciﬁed for the intended
dose. Pills administered at least 30 minutes apart from each other were considered different actual doses.
3By self-report, number of pills taken was missing for one dose for 2 patients for the 1x6 blister pack, 1 patient for the 2x6 blister pack, and 8 patients for
the 4x6 blister pack.
46 patients reported taking all pills, but since pills remained in the blister pack, they were not considered to have completed treatment (4 patients taking
the 1x6 pack, 1 patient for the 2x6 pack, and 1 patient for the 4x6 pack). 1 patient for the 2x6 pack and 2 patients for the 4x6 blister reported taking no
actual doses.
doi:10.1371/journal.pone.0134275.t004
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doses. However, patients may have taken pills grouped in a way that differed from the intended
doses in the blister packs, and may therefore have taken more than six actual doses, as smart
blister pack data indicated was the case. If any actual doses beyond the six intended are not cap-
tured by self-report interviews, this could underestimate the percentage completing treatment.
In order to avoid some of these challenges, data collection tools need to be improved and evalu-
ated, for example, including both open and closed-ended questions to identify actual doses
taken [6].
As part of both the completed treatment and timely completion definitions, self-report was
verified by counting pills remaining in packaging for the 83% of patients that presented blister
packs. Very few patients (9/696) reported completing treatment but had pills remaining, simi-
lar to the high concordance between self-report alone and pill count described in a review of
adherence to medication across diseases [3]. While this suggests that definitions incorporating
pill counts may not differ from self-report alone, the patients who did not present blister packs
reported higher completed treatment than those who did present blister packs (85% vs. 68%).
This suggests that requesting blister packs may reduce over-reporting of adherence, unless
patients for whom blister packs were not available were more likely to have finished packs and
disposed of them. Blister packs were requested at the end of the questionnaire, which means
patients could have removed pills from the pack after completing the interview but prior to
presenting the pack.
Compared to smart blister packs, self-report generally over-reported timely completion,
consistent with most other studies of electronic monitoring of adherence across diseases [4].
However, 27% (41/155) of patients with timely completion by smart blister pack data did not
report timely completion (S2 Table). This is likely due to patient confusion when reporting
Fig 4. Timely completion for each actual dose and cumulatively1. 155 patients were excluded from this analysis because data on timing of each actual
dose were not possible to assess for self-report for 18 patients and for smart blister pack data for 37 patients.
doi:10.1371/journal.pone.0134275.g004
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dose history, which was noted frequently by study staff, or possibly removing pills for later con-
sumption. Studies of adherence to tuberculosis treatment and antiretroviral therapy have also
documented that some patients non-adherent by self-report were adherent by electronic pill
containers [10, 11]. Our smart blister pack data revealed how some patients took pills in more
than six actual doses, or removed a large number of pills at once, including removal of all pills
remaining in the packaging on the date of the interview—possibly at the time of the interview.
The smart blister packs were easy to assemble, the software and portable scanner were
straightforward to use, and the packs were designed to look identical to regular AL packs com-
monly available in Tanzania. However, they had a slight bulge at the top of the package for a
small chip that stored data. Some patients noticed this and opened up the packaging to investi-
gate, damaging the capacity to record and extract timestamps. Several patients were alarmed
when the chip was discovered, requiring the study team to provide full explanations to partici-
pants and village leaders. Other blister packs were destroyed when children were allowed to
play with them after completion of treatment, or when dropped in water or fires before, during,
or after taking pills.
Although smart blister packs accurately recorded when pills were removed from the packag-
ing, it was also possible for a timestamp to be recorded for a pill if pressure had been applied
and a pill was partially removed, even if the seal was not obviously broken. While it was evident
when timestamps were recorded before the treatment was dispensed to the patient or after the
pack was collected, this could also have occurred in the middle of treatment, which could have
altered timely completion estimates, though this is not thought to have occurred frequently. In
addition, for some patients, the number of pills observed by the study team at scanning did
not correspond with the number read by the software. Future smart blister pack designs should
be improved to reduce the chances that timestamps would be recorded when pills weren’t
completely removed and to reduce the bulge in the packaging so that patients are less likely to
notice and tamper with the packaging.
Another approach to getting insights into adherence is through the measurement of drug
levels in patients’ blood during follow-up. In the case of ACTs, this has been approached by
measuring the concentration of the non-artemisinin partner drug since the artemisinin compo-
nent is absorbed and eliminated rapidly [26]. We collected blood spots on filter paper for the
assessment of lumefantrine concentrations. However, analysis 19–24 months after collection
found lumefantrine concentrations below the lower limit of quantification, reflecting the need
for filter papers to be stored at appropriate temperatures and ideally analysed within 4–6 weeks
post-collection [27].
Moreover, studies of adherence to AL have not found significant differences in blood lume-
fantrine concentrations between patients considered adherent and non-adherent by self-report
[8, 28–30]. Some studies have reported significant differences in lumefantrine concentrations
(usually measured 7 days after initiation of treatment) between supervised versus non-super-
vised patients [31–33]. These and other studies have not reported differences in treatment
failure based on cut-offs of 280 ng / ml [29, 31–33] or 175 ng / ml [8], which have been previ-
ously found to predict recrudescence [12, 26]. In addition, lumefantrine is known to have high
inter-individual metabolic variation, with factors such as weight, age, pregnancy, and fat intake
affecting absorption [34–36]. As a result, while biological measures of lumefantrine concentra-
tion might provide some additional objective information about adherence, they can be diffi-
cult to obtain, process and interpret in follow-up studies.
Finally, methods for measuring adherence should be based on levels and components of
adherence that are important for effectiveness. For example, it might be expected that complet-
ing treatment is more important than exact timing of doses. The recommended regimen for
AL was developed in early trials showing that a six-dose regimen of AL taken twice per day,
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with the second dose taken after eight hours, resulted in higher cure rates than a four-dose regi-
men [34, 37, 38]. However, it is unclear how strictly dose intervals must be adhered to in order
for treatment to be effective. Patients who obtain ACTs in the evening may be less likely to
adhere to correct dose timing than patients who obtain ACTs in the morning, and it is unclear
to what extent this matters. As adherence needs to be defined and measured depending on
what is required for drug effectiveness, the importance of exact dose timing must be clarified.
Conclusion
Accurate measurements of patient adherence are important for developing strategies to assure
the effectiveness of ACTs. While self-reported data along with examination of packaging might
be sufficient to assess completion of treatment, patient reports of timely completion appear to
be affected by both recall and/or social desirability bias. Smart blister packs provided slightly
lower, and potentially more accurate, estimates of the number of pills taken for each dose and
the time intervals between doses. In settings where data on dose timing are considered impor-
tant for clinical outcomes, smart blister packs may be a useful tool, though innovations to
make them more robust and discreet would be useful. Improved methods for collecting self-
reported data are also likely to enhance the accuracy of measured patient adherence to treat-
ment. Finally, a clearer rationale for what is considered adequate adherence is required.
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